ETNB — 89bio Share Price
Last Trade - 00:00- $361.89m
- $172.26m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | |||
| EPS Growth (f) | |||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | |||
| Price to Tang. Book | |||
| Price to Free Cashflow | |||
| Price to Sales | |||
| EV to EBITDA | |||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | |||
| Return on Equity | |||
| Operating Margin | |||
Financial Summary
| Year End 31st Dec | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | 1.43 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
89bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The Company’s lead product candidate, BIO89-100, a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is being developed for the treatment of nonalcoholic steatohepatitis (NASH). FGF21 is a metabolic hormone that regulates energy expenditure and glucose and lipid metabolism.
Directors
- Steven Altschuler (67)
- Rohan Palekar (55)
- Ryan Martins (44)
- Ram Waisbourd (54)
- Quoc Le-Nguyen (53)
- Hank Mansbach (56)
- Derek Dirocco (40)
- Gregory Grunberg (48)
- Michael Hayden (69)
- Anat Naschitz (53)
- Lota Zoth (61)
- Last Annual
- December 31st, 2020
- Last Interim
- March 31st, 2021
- Incorporated
- June 28th, 2019
- Public Since
- November 11th, 2019
- No. of Shareholders
- 12
- No. of Employees
- 26
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 20,060,268
- Address
- 535 Mission St Fl 14, San Francisco, 94105-3253
- Web
- https://www.89bio.com/
- Phone
- +1 4155004614
- Auditors
- Deloitte & Touche LLP
Latest News for ETNB
Upcoming events for ETNB
Q3 2021 89Bio Inc Earnings Release
Q3 2021 89Bio Inc Earnings Release
Similar to ETNB
4D PHARMA ADR REP 8 ORD
NASDAQ Global Market
ACCELERON PHARMA ORD
NASDAQ Global Market
ACELRX PHARMACEUTICALS ORD
NASDAQ Global Market
ADAGENE 4 ADR REP 5 ORD
NASDAQ Global Market
ADAGIO THERAPEUTICS ORD
NASDAQ Global Market
FAQ
As of Today at 19:53 UTC, shares in 89bio are trading at $18.04. This share price information is delayed by 15 minutes.
Shares in 89bio last closed at $18.04 and the price had moved by -43.18% over the past 365 days. In terms of relative price strength the 89bio share price has underperformed the S&P500 Index by -56.89% over the past year.
The overall consensus recommendation for 89bio is Buy. You can view the full broker recommendation list by unlocking its StockReport.
89bio does not currently pay a dividend.
89bio does not currently pay a dividend.
89bio does not currently pay a dividend.
To buy shares in 89bio you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $18.04, shares in 89bio had a market capitalisation of $361.89m.
Here are the trading details for 89bio:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: ETNB
Based on an overall assessment of its quality, value and momentum 89bio is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in 89bio is $52.50. That is 191.02% above the last closing price of $18.04.
Analysts covering 89bio currently have a consensus Earnings Per Share (EPS) forecast of -$3.33 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like 89bio. Over the past six months, its share price has underperformed the S&P500 Index by -34.49%.
As of the last closing price of $18.04, shares in 89bio were trading -19.92% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We are not able to find PE ratio data for 89bio.
89bio's management team is headed by:
- Steven Altschuler -
- Rohan Palekar -
- Ryan Martins -
- Ram Waisbourd -
- Quoc Le-Nguyen -
- Hank Mansbach -
- Derek Dirocco -
- Gregory Grunberg -
- Michael Hayden -
- Anat Naschitz -
- Lota Zoth -
We do not have data on 89bio's shareholders